ATLANTA – Alzamend Neuro, Inc. (NASDAQ:ALZN), a biopharmaceutical firm engaged within the improvement of remedies for neurological problems, has introduced the completion of a nonclinical examine that means its investigational lithium remedy, AL001, could provide therapeutic advantages for Alzheimer’s illness and different neurological circumstances with a doubtlessly improved security profile.
The examine, performed on the College of South Florida and analyzed by Sannova Analytical LLC, in contrast the mind and plasma lithium ranges achieved by AL001 to these of lithium carbonate, a present FDA-approved remedy. Within the examine, 5XFAD mice, a mannequin for Alzheimer’s analysis, acquired various doses of each substances over a two-week interval. The findings indicated that AL001 led to persistently greater lithium concentrations in essential mind areas at decrease doses than lithium carbonate, whereas additionally displaying decrease plasma lithium ranges, suggesting a decreased threat of opposed systemic results.
These outcomes might have vital implications for sufferers with Alzheimer’s, bipolar dysfunction, main depressive dysfunction, and post-traumatic stress dysfunction, as they recommend that AL001 could ship brain-specific lithium remedy extra successfully and with fewer negative effects. The decreased systemic publicity noticed with AL001 implies a doubtlessly safer therapeutic index for lithium, which can alleviate the necessity for routine blood lithium monitoring and scale back the danger of thyroid and kidney problems.
Alzamend’s CEO, Stephan Jackman, expressed optimism concerning the examine’s outcomes, stating that the information will information the upcoming “Lithium in Brain” Part II scientific trials in partnership with Massachusetts Common Hospital. These trials will assess AL001 in wholesome topics and sufferers identified with delicate to average Alzheimer’s and different circumstances, primarily based on the dosing stage deemed applicable from the nonclinical examine.
Alzamend’s pipeline additionally consists of AL002, a cell-based therapeutic vaccine for Alzheimer’s. Each AL001 and AL002 are licensed from the College of South Florida Analysis Basis, Inc.
Whereas these findings are encouraging, they’re primarily based on animal fashions, and the efficacy and security of AL001 in people will probably be additional evaluated within the forthcoming scientific trials. The data on this article is predicated on a press launch assertion from Alzamend Neuro, Inc.
In different current information, Alzamend Neuro has made vital strides in Alzheimer’s remedy with the profitable dedication of a most tolerated dose for its AL001 dementia remedy. The corporate has additionally regained compliance with Nasdaq’s stockholders’ fairness requirement via the sale of $25 million of its Collection A Convertible Most well-liked Inventory. Moreover, Alzamend Neuro has entered into an At-the-Market issuance gross sales settlement with Ascendiant Capital Markets, facilitating the sale of frequent inventory as much as $6.5 million. Ascendiant Capital has adjusted its outlook on Alzamend Neuro, lowering the 12-month value goal to $21 from the earlier $25, whereas sustaining a Purchase ranking on the inventory.
The corporate has launched a number of Part II scientific trials in collaboration with Massachusetts Common Hospital for its therapeutic drug candidates AL001 and ALZN002. These trials goal to guage elevated lithium ranges within the mind, doubtlessly enhancing remedies for Alzheimer’s, bipolar dysfunction, main depressive dysfunction, and post-traumatic stress dysfunction. Alzamend Neuro has additionally introduced a one-for-ten reverse inventory cut up and initiated a major conversion of most well-liked inventory into frequent shares and warrants, doubtlessly permitting for a purchase order value of as much as $25 million. These are current developments in Alzamend Neuro’s ongoing efforts within the biopharmaceutical sector.
InvestingPro Insights
Whereas Alzamend Neuro’s current examine outcomes for AL001 are promising, traders ought to take into account the corporate’s monetary place and market efficiency. Based on InvestingPro information, Alzamend’s market capitalization stands at a modest $6.04 million, reflecting its early-stage standing in drug improvement.
InvestingPro Ideas spotlight some challenges dealing with the corporate. Alzamend is “quickly burning through cash” and “suffers from weak gross profit margins,” which isn’t unusual for biotech corporations within the analysis and improvement part. The corporate’s monetary well being is additional underscored by the truth that its “short term obligations exceed liquid assets,” though it “holds more cash than debt on its balance sheet.”
The inventory’s current efficiency has been regarding, with InvestingPro information displaying a 19.4% decline up to now month and a considerable 92.01% drop over the past 12 months. This aligns with the InvestingPro Tip that the “stock has taken a big hit over the last week” and is “trading near 52-week low.”
Buyers ought to notice that analysts “do not anticipate the company will be profitable this year,” which is in line with the character of early-stage biopharmaceutical corporations investing closely in analysis and improvement.
For a extra complete evaluation, InvestingPro gives 16 extra recommendations on Alzamend Neuro, offering deeper insights into the corporate’s monetary well being and market place.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.
